Pharmaceutical

CinDome Pharma secures $40m to advance gastroparesis treatment

CinDome Pharma has secured $40m in a Series B financing extension round to develop deudomperidone for chronic gastroparesis.

May 19, 2024 - 04:00
CinDome Pharma secures $40m to advance gastroparesis treatment
CinDome Pharma has secured $40m in a Series B financing extension round to develop deudomperidone for chronic gastroparesis.
Read the original article

Tags:

Previous Article

FDA grants breakthrough therapy status for Nuvalent’s NVL-655

Next Article

Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NIH nominee Bertagnolli will get a confirmation hearing next month, Sanders says

NIH nominee Bertagnolli will get a confirmation hearing...

Sep 8, 2023

NHS launches “game-changer” and lifesaving anti-smoking pill

NHS launches “game-changer” and lifesaving anti-smoking...

Nov 13, 2024

Apple and Anthem’s experimental asthma app shows early promise but its future is uncertain

Apple and Anthem’s experimental asthma app shows early ...

Nov 9, 2023